Researchers Find No Clear Paths on Road to Unraveling Schizophrenia

Twenty years ago, many investigators believed that genetics held the key to understanding schizophrenia, an etiologically heterogeneous disease.1 It seemed only a matter of time before the power of genetic analysis could be brought to bear on this malady, resulting in better drug leads and better ways toward prevention.2 So far, genetic advances have been few. "There was really a misjudgment on the part of some in the field," says Kenneth Kendler, professor of psychiatry and human genetics at

Written byEugene Russo
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

So far, genetic advances have been few. "There was really a misjudgment on the part of some in the field," says Kenneth Kendler, professor of psychiatry and human genetics at Virginia Commonwealth University. Today, the disease's other potential causes, working in tandem with schizophrenia's genetic component, are receiving considerable attention as well.

Many who participated had preconceived notions about the sample sizes required to mount the necessary statistical gene-finding power. Steven Moldin, chief of the NIMH's Genetics Research Branch, says that researchers expected 100 families would do the trick. As it turned out, that number was off by an order of magnitude.

Some investigators presumed they would find a straightforward relationship between gene and disease, but they learned that with schizophrenia, as with other complex diseases, simple Mendelian genetics did not apply. Moreover, researchers underestimated the number of loci across the genome that could be involved and the degree of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies